Middletown Life

Author: NEKTAR THERAPEUTICS

Nektar Therapeutics Announces Proposed Public Offering

February 13, 2026
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

February 12, 2026
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

February 12, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 8, 2026
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

December 16, 2025
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 6, 2025
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 2, 2025